WallStreetZenWallStreetZen

NASDAQ: CHRS
Coherus Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CHRS

Based on 1 analyst offering 12 month price targets for Coherus Oncology Inc

Min Forecast
$4.00+194.12%
Avg Forecast
$4.00+194.12%
Max Forecast
$4.00+194.12%

Should I buy or sell CHRS stock?

Based on 1 analyst offering ratings for Coherus Oncology Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CHRS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CHRS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CHRS stock forecasts and price targets.

CHRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-04

1 of 1

Forecast return on equity

Is CHRS forecast to generate an efficient return?

Company
-127.82%
Industry
353.57%
Market
208.87%
CHRS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CHRS forecast to generate an efficient return on assets?

Company
-21.72%
Industry
119.32%
CHRS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CHRS earnings per share forecast

What is CHRS's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.95-171.47%
Avg 2 year Forecast
-$0.85-164.04%
Avg 3 year Forecast
-$1.14-185.89%

CHRS revenue forecast

What is CHRS's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$74.7M-10.65%
Avg 2 year Forecast
$98.2M+17.57%
Avg 3 year Forecast
$189.6M+126.83%
CHRS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CHRS revenue growth forecast

How is CHRS forecast to perform vs Biotechnology companies and vs the US market?

Company
27.88%
Industry
113.47%
Market
23.09%
CHRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CHRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CHRS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CHRS$1.36$4.00+194.12%Strong Buy
TLSA$1.48N/AN/A
MOLN$4.38$3.75-14.38%Hold
IMMX$4.95$12.00+142.42%Buy
RANI$1.38$10.50+660.87%Strong Buy
View Top Biotech Stocks

Coherus Oncology Stock Forecast FAQ

Is Coherus Oncology Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CHRS) stock is to Strong Buy CHRS stock.

Out of 1 analyst, 1 (100%) are recommending CHRS as a Strong Buy, 0 (0%) are recommending CHRS as a Buy, 0 (0%) are recommending CHRS as a Hold, 0 (0%) are recommending CHRS as a Sell, and 0 (0%) are recommending CHRS as a Strong Sell.

If you're new to stock investing, here's how to buy Coherus Oncology stock.

What is CHRS's earnings growth forecast for 2026-2028?

(NASDAQ: CHRS) Coherus Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.

Coherus Oncology's earnings in 2026 is $154,971,000.On average, 8 Wall Street analysts forecast CHRS's earnings for 2026 to be -$114,899,985, with the lowest CHRS earnings forecast at -$164,650,494, and the highest CHRS earnings forecast at -$63,457,282. On average, 7 Wall Street analysts forecast CHRS's earnings for 2027 to be -$102,945,842, with the lowest CHRS earnings forecast at -$146,882,455, and the highest CHRS earnings forecast at -$59,649,845.

In 2028, CHRS is forecast to generate -$138,083,045 in earnings, with the lowest earnings forecast at -$132,668,024 and the highest earnings forecast at -$142,144,311.

What is CHRS's revenue growth forecast for 2026-2028?

(NASDAQ: CHRS) Coherus Oncology's forecast annual revenue growth rate of 27.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.09%.

Coherus Oncology's revenue in 2026 is $83,568,000.On average, 7 Wall Street analysts forecast CHRS's revenue for 2026 to be $9,025,559,412, with the lowest CHRS revenue forecast at $7,344,122,750, and the highest CHRS revenue forecast at $11,373,599,710. On average, 7 Wall Street analysts forecast CHRS's revenue for 2027 to be $11,875,214,414, with the lowest CHRS revenue forecast at $3,840,313,825, and the highest CHRS revenue forecast at $17,289,389,700.

In 2028, CHRS is forecast to generate $22,912,309,224 in revenue, with the lowest revenue forecast at $21,472,735,459 and the highest revenue forecast at $24,703,617,637.

What is CHRS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CHRS) forecast ROA is -21.72%, which is lower than the forecast US Biotechnology industry average of 119.32%.

What is CHRS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CHRS price target, the average CHRS price target is $4.00, with the highest CHRS stock price forecast at $4.00 and the lowest CHRS stock price forecast at $4.00.

The Wall Street analyst predicted that Coherus Oncology's share price could reach $4.00 by Sep 4, 2026. The average Coherus Oncology stock price prediction forecasts a potential upside of 194.12% from the current CHRS share price of $1.36.

What is CHRS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CHRS) Coherus Oncology's current Earnings Per Share (EPS) is $1.33. On average, analysts forecast that CHRS's EPS will be -$0.95 for 2026, with the lowest EPS forecast at -$1.36, and the highest EPS forecast at -$0.53. On average, analysts forecast that CHRS's EPS will be -$0.85 for 2027, with the lowest EPS forecast at -$1.22, and the highest EPS forecast at -$0.49. In 2028, CHRS's EPS is forecast to hit -$1.14 (min: -$1.10, max: -$1.18).

What is CHRS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CHRS) forecast ROE is -127.82%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.